This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Richard C. Reichman, MD; David M. Markovitz, MD
The University of Rochester Medical Center Rochester, NY

JAMA. 1986;256(11):1443-1444.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

We appreciate the comments of Dr Fiumara regarding our recently published case report. The article describes a case of clinical relapse of secondary syphilis after treatment with the CDC's recommended regimen.^1,2 It was not our intention to indicate that the CDC guidelines are "inadequate" but rather to demonstrate that failures do occur and to stress the importance of careful follow-up. In fact, we suggest that the present regimen should continue to be employed until appropriately controlled studies demonstrate superiority of an alternative approach.

We are familiar with Dr Fiumara's extensive experience using a total of 4.8 million units of penicillin G benzathine intramuscularly to treat primary and secondary syphilis. We take issue, however, with his suggestion that a study comparing 2.4 and 4.8 million units of intramuscular penicillin G benzathine has already been performed. In the study to which he refers,³ a treatment arm employing 4.8 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?